European Commission Approves Biosimilar Imraldi for Crohn’s Disease and Ulcerative Colitis

European Commission Approves Biosimilar Imraldi for Crohn’s Disease and Ulcerative Colitis
The European Commission has approved Imraldi, an adalimumab biosimilar referencing AbbVie’s Humira — making the medication available to treat the same therapeutic indications as Humira, including Crohn’s disease, pediatric Crohn’s disease and ulcerative colitis. The Aug. 24 decision followed a positive recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use, released in June. “Today’s decision marks another positive step in transforming the lives of people with chronic autoimmune conditions,” Jean-Paul Kress, Biogen's executive vice-president and head of global therapeutic operations, said in a press release. “As the number of approved biosimilars continues to grow, so does the anticipated potential to increase physician choice and patient access to biologics.” Imraldi was developed by Samsung Bioepis, a joint venture between Biogen and Samsung BioLogics. It is Biogen’s tgurd anti-TNF biosimilar medicine to receive European marketing approval following Benepali, an etanercept biosimilar referencing Enbrel, and Flixabi, an infliximab biosimilar referencing Remicade. The approval was supported by strong preclinical and clinical data demonstrating Imraldi's
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *